Avalyn Pharma AVLN 深 沪
已收盘 09-25 16:00:00 美东时间
28.08
-0.470
-1.65%
华盛通- 最 高28.525
- 今 开28.52
- 成交量 22.31万股
- 最 低 27.00
- 昨 收 28.55
- 总市值 12.45亿
- 52周最高 40.17
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 24.15
- 委 比 -97.33%
- 总股本 4433.31万
- 历史最高 40.17
- 量 比 0.72
- 振 幅 5.34%
- 历史最低 24.15
- 每 手 1
- 风险率 3.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Avalyn Pharma's AP02, an inhaled nintedanib, showed favorable safety, tolerability, and significantly higher lung exposure with lower systemic exposure compared to oral nintedanib in Phase 1 trials. Results support its potential to enhance efficacy and reduce side effects for IPF treatment. The AURA Phase 2 trial is ongoing with topline data expected late 2027.
09-21 13:00
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
Avalyn Pharma announced the appointment of Robert J. Meyer, MD, a renowned pulmonologist and former FDA leader, to its Board of Directors. Dr. Meyer brings extensive experience in respiratory drug development and regulatory affairs, having previously worked at the FDA and Merck. His expertise will support Avalyn's inhaled therapies for pulmonary fibrosis, including its AP01, AP02, and AP03 programs, which aim to improve treatment efficacy and red...
09-16 20:01
Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of potential benefits and risks, and efforts to reduce logistical burden may support engagement in future pulmo...
09-08 20:05
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
Avalyn Pharma announced new data at the ERS Congress 2026, highlighting robust delivery of AP01 to fibrotic lung areas and patient insights on clinical trial participation. In silico modeling showed consistent aerosol distribution across healthy, mild, and severe IPF lungs, with effective targeting of fibrotic tissues. Patient surveys revealed strong interest in trials, emphasizing the need for clear communication, risk-benefit discussions, and l...
09-08 12:00
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Avalyn Pharma reports Q2 results
Avalyn Pharma press release (AVLN): Q2 Net loss was $28.9 million for the second quarter of 2026, as compared to $20.2 million for the second quarter of 2025. Cash Position: Cash, cash equivalents, a...
08-13 01:02
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
08-12 22:11
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
08-12 20:13
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma Inc. announced the completion of global enrollment for its MIST Phase 2b trial of AP01 with 398 patients, with topline data expected in late 2027. The company also reported two abstracts accepted for presentation at the European Respiratory Society Congress, focusing on AP01 lung tissue distribution and patient perspectives. As of June 30, 2026, Avalyn held $413.5 million in cash, with a cash runway projected into 2029. Recent progr...
08-12 12:00
